APPLICATION OF BIOLOGICALLY ACTIVE COMPLEX ANDRODOZ® IN PATIENTS WITH PATHOSPERMIA AND IMMUNOLOGICAL FACTOR OF INFERTILITY . RESULTS OF MULTICENTER CLINICAL TRIAL
A.A. Kamalov (1), I.A. Aboyan (2), M.E. Sitdykova (3), A.Y. Tsukanov (4), O.V. Teodorovich (5), V.L. Medvedev (6), B.K. Komyakov (7), V.N. Zhuravlev (8), A.I. Novikov (7), A.A. Erkovich (9), D.A. Okhobotov (1), V.K. Karpov (1), A.Yu.Zubkov (3)
(1) Department of Urology and Andrology FFM MSU n.a. M.V. Lomonosov, Moscow; (2) MMPHCI MDC "Health", Rostov-on-Don; (3) Department of Urology, Kazan State Medical University, Kazan;(4) Department of Surgical Diseases and Urology, Faculty of Postgraduate Education SBEI HPE "Omsk State Academy" of RMPH, Omsk; (5) Department of Endoscopic Urology RMAPE, Moscow; (6) Department of Urology FATPRS of Krasnodar SMU, Krasnodar; (7) Department of Urology SBEI HPE NWSMU n.a. I.I. Mechnikov, St. Petersburg; (8) Department of Urology of the Ural State Medical Academy, Yekaterinburg; (9) Department of Urology of the Novosibirsk State Medical University, Novosibirsk
The study involved 73 patients from different regions of the Russian Federation in age from 20 to 65 years (mean age – 34.32 ± 7.9 years) with various types of pathospermia and duration of infertile marriage from 14 months to 4 years (mean duration 22.27 ±17.1 months). These patients were divided into two groups with the presence of anti-sperm antibodies (ASAB), and without them; in patients with ASAB, subgroup with clinically significant ASAB levels more than 10% was further identified. All patients received AndroDoz® for 3 months. All patients underwent spermatologic control, monitoring of blood and urine tests, blood biochemistry and hormones, the evaluation of anti-sperm antibodies levels, and immunoglobulins A and G levels. After 3 months of therapy, it was found that patients receiving AndroDoz® had significantly reduced viscosity of spermoplasma, especially patients with ASAB.vAt the same time, patients with ASAB had decreased sperm agglutination by 80.1 % (P = 0.0001), increased total number of actively motile sperm cells (A + B), and decreased number of pathological forms of sperm cells by 26.32 % (P = 0.0001, with normalization of this index in 100% of patients with an initial critical increase ( > 96% abnormal forms) at the end of therapy). Moreover, patients receiving AndroDoz ® had significantly increased Inhibin B levels. At the end of the course of therapy, 87.6 % of patients have reported good and pronounced effect of the treatment. AndroDoz ® has shown to be effective in treating infertility and pathospermia of various origins with a high degree of reliability of the results.
About the Autors
D.A.Okhobotov – PhD in Medical Sciences, Senior Teacher at the Department of Urology and Andrology FFM MSU n.a. M.V. Lomonosov; e-mail: firstname.lastname@example.org